Effects of Different Omeprazole Dosing on Gastric pH in Non-variceal Upper Gastrointestinal Bleeding

Non-variceal Upper Gastrointestinal Bleeding Clinical Trial

Official title: Effects of Different Omeprazole Dosing on Gastric pH in Non- Variceal Upper Gastrointestinal Bleeding: A Randomized Prospective Study

Status Completed

Clinical Trial Summary

The aim of the study is to identify the best method of omeprazole (OME) application with respect to intragastric pH, cytochrome P450 2C19 (CYP2C19) genotype and phenotype.

Clinical Trial Description

The patients with non-variceal upper gastrointestinal bleeding (NVUGIB) are prospectively enrolled. After the achievement of endoscopic hemostasis, the patients are randomized to 40-mg intravenous (i.v.) OME bolus injection every 12 h or 8-mg/h continuous i.v. infusion for 72 h after an 80-mg i.v. OME bolus administration. The intragastric pH is recorded for 72 h. The CYP2C19 variant alleles (*2, *3, *17) are analyzed and the serum concentrations of OME and 5-hydroxyomeprazole (5-OH OME) are determined. The diagnosis of Helicobacter pylori infection was based on the results of the rapid urease test performed on stomach mucosa biopsies (antrum and angle) and on the results of the stool antigen test. ;

Related Conditions & MeSH terms

• Gastrointestinal Hemorrhage
• Hemorrhage
• Non-variceal Upper Gastrointestinal Bleeding

• NCT number: NCT03980496
• Study type: Interventional
• Source: Medical University of Bialystok
• Status: Completed
• Phase: Phase 4
• Start date: September 9, 2010
• Completion date: June 8, 2013